Global seroprevalence of SARS-CoV-2 antibodies: A systematic review and meta-analysis
Open accessPublished version of a preprint
The DOI matches its Crossref record; 52 of the 52 references it cites were found in a registry or an index.
Abstract
Background: Many studies report the seroprevalence of severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) antibodies. We aimed to synthesize seroprevalence data to better estimate the level and distribution of SARS-CoV-2 infection, identify high-risk groups, and inform public health decision making. Methods: In this systematic review and meta-analysis, we searched publication databases, preprint servers, and grey literature sources for seroepidemiological study reports, from January 1, 2020 to December 31, 2020. We included studies that reported a sample size, study date, location, and seroprevalence estimate. We corrected estimates for imperfect test accuracy with Bayesian measurement error models, conducted meta-analysis to identify demographic differences in the prevalence of SARS-CoV-2 antibodies, and meta-regression to identify study-level factors associated with seroprevalence. We compared region-specific seroprevalence data to confirmed cumulative incidence. PROSPERO: CRD42020183634. Results: We identified 968 seroprevalence studies including 9.3 million participants in 74 countries. There were 472 studies (49%) at low or moderate risk of bias. Seroprevalence was low in the general population (median 4.5%, IQR 2.4–8.4%); however, it varied widely in specific populations from low (0.6% perinatal) to high (59% persons in assisted living and long-term care facilities). Median seroprevalence also varied by Global Burden of Disease region, from 0.6% in Southeast Asia, East Asia and Oceania to 19.5% in Sub-Saharan Africa (p<0.001). National studies had lower seroprevalence estimates than regional and local studies (p<0.001). Compared to Caucasian persons, Black persons (prevalence ratio [RR] 3.37, 95% CI 2.64–4.29), Asian persons (RR 2.47, 95% CI 1.96–3.11), Indigenous persons (RR 5.47, 95% CI 1.01–32.6), and multi-racial persons (RR 1.89, 95% CI 1.60–2.24) were more likely to be seropositive. Seroprevalence was higher among people ages 18–64 compared to 65 and over (RR 1.27, 95% CI 1.11–1.45). Health care workers in contact with infected persons had a 2.10 times (95% CI 1.28–3.44) higher risk compared to health care workers without known contact. There was no difference in seroprevalence between sex groups. Seroprevalence estimates from national studies were a median 18.1 times (IQR 5.9–38.7) higher than the corresponding SARS-CoV-2 cumulative incidence, but there was large variation between Global Burden of Disease regions from 6.7 in South Asia to 602.5 in Sub-Saharan Africa. Notable methodological limitations of serosurveys included absent reporting of test information, no statistical correction for demographics or test sensitivity and specificity, use of non-probability sampling and use of non-representative sample frames. Discussion: Most of the population remains susceptible to SARS-CoV-2 infection. Public health measures must be improved to protect disproportionately affected groups, including racial and ethnic minorities, until vaccine-derived herd immunity is achieved. Improvements in serosurvey design and reporting are needed for ongoing monitoring of infection prevalence and the pandemic response.
Overview
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Integrity signals
Registry
Cites
Statistics
Figures



Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Claims other papers make about this one
Each is checked against this paper’s own text: does it say what the citing paper says it does?
The check wasn’t confident either way, so it gives no verdict — never disputed.
In the citing paper
“However, given the known variability in dual human data extraction accuracy (reported rates: 65.8-85.5%) 14-19 , original author-extracted values were not treated as a definitive gold standard”
From Automation of Systematic Reviews with Large Language Models (2025) · cites this paper as [14]
Experimental — accuracy not yet measuredThe check wasn’t confident either way, so it gives no verdict — never disputed.
In the citing paper
“Prior research has shown wide variability in the accuracy of dual human extraction, with reported rates ranging from 65.8-85.5% 14-19 .”
From Automation of Systematic Reviews with Large Language Models (2025) · cites this paper as [14]
Experimental — accuracy not yet measuredThe check wasn’t confident either way, so it gives no verdict — never disputed.
In the citing paper
“For human data extraction, we determined sample size using a McNemar test for sample size approximation. Using an estimated human accuracy of 80% (reported rates: 65.8-85.5%) 14-19 , LLM accuracy of 90%, and 95% confidence, we determined a minimum number of 204 variables per study to be extracted.”
From Automation of Systematic Reviews with Large Language Models (2025) · cites this paper as [14]
Experimental — accuracy not yet measured
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
Preferred Reporting Items for Systematic Reviews and Meta-Analyses: the PRISMA statement
Moher, D., Liberati, A., Tetzlaff, J., Altman, D. G., & for the PRISMA Group (2009) · BMJ · doi:10.1136/bmj.b2535 · Cited by 83,823
Preferred reporting items for systematic reviews and meta-analyses: the PRISMA Statement.
(2009) · PubMed Central · Cited by 44,859
Cochrane Handbook for Systematic Reviews of Interventions: Cochrane Book Series
(2008) · doi:10.1002/9780470712184 · Cited by 25,048
How to perform a meta-analysis with R: a practical tutorial
Balduzzi, S., Rücker, G., & Schwarzer, G. (2019) · Evidence Based Mental Health · doi:10.1136/ebmental-2019-300117 · Cited by 5,827 · cited 1×
“All meta-analysis and meta-regression were done using the meta package in R [34].”
MethodCochrane Handbook for Systematic Reviews of Interventions
Higgins, J. P. T., Green, S., & Ben Van Den, A. (2020) · International Coaching Psychology Review · doi:10.53841/bpsicpr.2020.15.2.123 · Cited by 5,670
Wiersinga, W. J., Rhodes, A., Cheng, A. C., Peacock, S. J., & Prescott, H. C. (2020) · JAMA · doi:10.1001/jama.2020.12839 · Cited by 4,609 · cited 1×
“Table 5: Differences in seroprevalence estimates by demographic characteristics within studies Factor Reference Group Comparison Group Number of Studies Risk Ratio (95% CI)a Heterogeneity (I 2) Age Adults (18-64) Youth (0-17) 82 0.”
BackgroundMunn, Z., Moola, S., Lisy, K., Riitano, D., & Tufanaru, C. (2015) · International Journal of Evidence-Based Healthcare · doi:10.1097/xeb.0000000000000054 · Cited by 3,131 · cited 1×
“A modified Joanna Briggs Institute (JBI) Critical Appraisal Checklist for Prevalence Studies was used to assess study risk of bias [17].”
MethodBi, Q., Wu, Y., Mei, S., Ye, C., Zou, X., Zhang, Z., Liu, X., Wei, L., Truelove, S. A., Zhang, T., et al. (2020) · The Lancet Infectious Diseases · doi:10.1016/s1473-3099(20)30287-5 · Cited by 1,958 · cited 1×
“Our review found that health care workers who had close contact with confirmed COVID19 cases had a higher risk of seropositivity, consistent with previous reports [45].”
ResultRobust neutralizing antibodies to SARS-CoV-2 infection persist for months
Wajnberg, A., Amanat, F., Firpo, A., Altman, D. R., Bailey, M. J., Mansour, M., McMahon, M., Meade, P., Mendu, D. R., Muellers, K., et al. (2020) · Science · doi:10.1126/science.abd7728 · Cited by 1,195
Buitrago-Garcia, D., Egli-Gany, D., Counotte, M. J., Hossmann, S., Imeri, H., Ipekci, A. M., Salanti, G., & Low, N. (2020) · PLOS Medicine · doi:10.1371/journal.pmed.1003346 · Cited by 1,000 · cited 1×
“However, these case counts inevitably underestimate the true cumulative incidence of infection [3] because of limited diagnostic test availability [4], barriers to testing accessibility [5], and asymptomatic infections [6].”
BackgroundAntibody tests for identification of current and past infection with SARS‐CoV‐2
Geppert, J., Scandrett, K., Bigio, J., Sulis, G., Hettiarachchi, D., Mathangasinghe, Y., Weeratunga, P., Wickramasinghe, D., Bergman, H., Buckley, S. B., et al. (2022) · LSTM Online Archive (Liverpool School of Tropical Medicine) · Cited by 850
Diagnostic accuracy of serological tests for covid-19: systematic review and meta-analysis
Lisboa Bastos, M., Tavaziva, G., Abidi, S. K., Campbell, J. R., Haraoui, L.-P., Johnston, J. C., Lan, Z., Law, S., MacLean, E., Trajman, A., et al. (2020) · BMJ · doi:10.1136/bmj.m2516 · Cited by 832
Persistence of serum and saliva antibody responses to SARS-CoV-2 spike antigens in COVID-19 patients
Isho, B., Abe, K. T., Zuo, M., Jamal, A. J., Rathod, B., Wang, J. H., Li, Z., Chao, G., Rojas, O. L., Bang, Y. M., et al. (2020) · Science Immunology · doi:10.1126/sciimmunol.abe5511 · Cited by 822
(2020) · doi:10.3138/jammi-2020-0030 · Cited by 664
Antibody tests for identification of current and past infection with SARS-CoV-2
Deeks, J. J., Dinnes, J., Takwoingi, Y., Davenport, C., Spijker, R., Taylor-Phillips, S., Adriano, A., Beese, S., Dretzke, J., Ferrante di Ruffano, L., et al. (2020) · Cochrane Database of Systematic Reviews · doi:10.1002/14651858.cd013652 · Cited by 655 · cited 1×
“Systematic reviews of SARS-CoV-2 serological test accuracy have found that many tests have poor sensitivity and specificity.(15,16) Of the studies included here, only 69 (20.”
BackgroundDiagnostic Testing for Severe Acute Respiratory Syndrome–Related Coronavirus 2: A Narrative Review
Cheng, M. P., Papenburg, J., Desjardins, M., Kanjilal, S., Quach, C., Libman, M., Dittrich, S., & Yansouni, C. P. (2020) · Annals of Internal Medicine · doi:10.7326/m20-1301 · Cited by 593 · cited 1×
“However, these case counts inevitably underestimate the true cumulative incidence of infection [3] because of limited diagnostic test availability [4], barriers to testing accessibility [5], and asymptomatic infections [6].”
BackgroundSelf-citationThe impact of ethnicity on clinical outcomes in COVID-19: A systematic review
Pan, D., Sze, S., Minhas, J. S., Bangash, M. N., Pareek, N., Divall, P., Williams, C. M., Oggioni, M. R., Squire, I. B., Nellums, L. B., et al. (2020) · EClinicalMedicine · doi:10.1016/j.eclinm.2020.100404 · Cited by 519 · cited 1×
“Some of these groups (Black, Asian, and other minority racial and ethnic groups) are also known to have higher infection fatality rates [44].”
BackgroundMathur, R., Rentsch, C. T., Morton, C. E., Hulme, W. J., Schultze, A., MacKenna, B., Eggo, R. M., Bhaskaran, K., Wong, A. Y. S., Williamson, E. J., et al. (2021) · The Lancet · doi:10.1016/s0140-6736(21)00634-6 · Cited by 501
SARS-CoV-2 seroprevalence worldwide: a systematic review and meta-analysis
Rostami, A., Sepidarkish, M., Leeflang, M. M. G., Riahi, S. M., Nourollahpour Shiadeh, M., Esfandyari, S., Mokdad, A. H., Hotez, P. J., & Gasser, R. B. (2021) · Clinical Microbiology and Infection · doi:10.1016/j.cmi.2020.10.020 · Cited by 369
Moore, J. T., Ricaldi, J. N., Rose, C. E., Fuld, J., Parise, M., Kang, G. J., Driscoll, A. K., Norris, T., Wilson, N., Rainisch, G., et al. (2020) · MMWR. Morbidity and Mortality Weekly Report · doi:10.15585/mmwr.mm6933e1 · Cited by 360
No association of COVID-19 transmission with temperature or UV radiation in Chinese cities
Yao, Y., Pan, J., Liu, Z., Meng, X., Wang, W., Kan, H., & Wang, W. (2020) · European Respiratory Journal · doi:10.1183/13993003.00517-2020 · Cited by 339 · cited 1×
“Given the limited evidence for altitude or climate effects on SARS-CoV-2 transmission [36, 37] variations in seroprevalence likely reflect differences in community transmission based on behaviour, public health responses, local resources, and the built environment.”
BackgroundCase-Fatality Risk Estimates for COVID-19 Calculated by Using a Lag Time for Fatality
Wilson, N., Kvalsvig, A., Barnard, L. T., & Baker, M. G. (2020) · Emerging Infectious Diseases · doi:10.3201/eid2606.200320 · Cited by 316 · cited 1×
“Table 5: Differences in seroprevalence estimates by demographic characteristics within studies Factor Reference Group Comparison Group Number of Studies Risk Ratio (95% CI)a Heterogeneity (I 2) Age Adults (18-64) Youth (0-17) 82 0.”
BackgroundJackson, J. L., Kuriyama, A., Anton, A., Choi, A., Fournier, J.-P., Geier, A.-K., Jacquerioz, F., Kogan, D., Scholcoff, C., & Sun, R. (2019) · Annals of Internal Medicine · doi:10.7326/m19-0891 · Cited by 290 · cited 1×
“Articles not in English or French were included if they could be fully extracted using machine translation [16].”
MethodDisparities in COVID-19 Testing and Positivity in New York City
Lieberman-Cribbin, W., Tuminello, S., Flores, R. M., & Taioli, E. (2020) · American Journal of Preventive Medicine · doi:10.1016/j.amepre.2020.06.005 · Cited by 288
Gallais, F., Velay, A., Nazon, C., Wendling, M.-J., Partisani, M., Sibilia, J., Candon, S., & Fafi-Kremer, S. (2021) · Emerging Infectious Diseases · doi:10.3201/eid2701.203611 · Cited by 267
Byambasuren, O., Dobler, C. C., Bell, K., Rojas, D. P., Clark, J., McLaws, M.-L., & Glasziou, P. (2021) · PLOS ONE · doi:10.1371/journal.pone.0248946 · Cited by 250
Serological evidence of human infection with SARS-CoV-2: a systematic review and meta-analysis
Chen, X., Chen, Z., Azman, A. S., Deng, X., Sun, R., Zhao, Z., Zheng, N., Chen, X., Lu, W., Zhuang, T., et al. (2021) · The Lancet Global Health · doi:10.1016/s2214-109x(21)00026-7 · Cited by 239
Figueroa, J. F., Wadhera, R. K., Lee, D., Yeh, R. W., & Sommers, B. D. (2020) · Health Affairs · doi:10.1377/hlthaff.2020.01040 · Cited by 210
Ng, O. T., Marimuthu, K., Koh, V., Pang, J., Linn, K. Z., Sun, J., De Wang, L., Chia, W. N., Tiu, C., Chan, M., et al. (2021) · The Lancet Infectious Diseases · doi:10.1016/s1473-3099(20)30833-1 · Cited by 208 · cited 1×
“These results align with other evidence synthesis examining persons with and without COVID-19 exposure however, they conflict with studies of high-risk exposure, including health care workers [9, 46].”
ResultSeroTracker: a global SARS-CoV-2 seroprevalence dashboard
Arora, R. K., Joseph, A., Van Wyk, J., Rocco, S., Atmaja, A., May, E., Yan, T., Bobrovitz, N., Chevrier, J., Cheng, M. P., et al. (2021) · The Lancet Infectious Diseases · doi:10.1016/s1473-3099(20)30631-9 · Cited by 200
Self-citationAntibody tests for identification of current and past infection with SARS-CoV-2
Fox, T., Geppert, J., Dinnes, J., Scandrett, K., Bigio, J., Sulis, G., Hettiarachchi, D., Mathangasinghe, Y., Weeratunga, P., Wickramasinghe, D., et al. (2022) · Cochrane Database of Systematic Reviews · doi:10.1002/14651858.cd013652.pub2 · Cited by 199
Ward, H., Cooke, G. S., Atchison, C., Whitaker, M., Elliott, J., Moshe, M., Brown, J. C., Flower, B., Daunt, A., Ainslie, K., et al. (2021) · The Lancet Regional Health - Europe · doi:10.1016/j.lanepe.2021.100098 · Cited by 197
Papadopoulos, C., Chong, S. J. K., & Jaunoo, S. (2020) · IJS Short Reports · doi:10.1097/sr9.0000000000000007 · Cited by 167
Briz‐Redón, Á., & Serrano‐Aroca, Á. (2020) · Progress in Physical Geography Earth and Environment · doi:10.1177/0309133320946302 · Cited by 155 · cited 1×
“Given the limited evidence for altitude or climate effects on SARS-CoV-2 transmission [36, 37] variations in seroprevalence likely reflect differences in community transmission based on behaviour, public health responses, local resources, and the built environment.”
BackgroundDeclining prevalence of antibody positivity to SARS-CoV-2: a community study of 365,000 adultsPreprint
Ward, H., Cooke, G., Atchison, C. J., et al. (2020) · medRxiv · doi:10.1101/2020.10.26.20219725 · Cited by 154
Brandén, M., Aradhya, S., Kolk, M., Härkönen, J., Drefahl, S., Malmberg, B., Rostila, M., Cederström, A., Andersson, G., & Mussino, E. (2020) · The Lancet Healthy Longevity · doi:10.1016/s2666-7568(20)30016-7 · Cited by 151 · cited 1×
“Table 5: Differences in seroprevalence estimates by demographic characteristics within studies Factor Reference Group Comparison Group Number of Studies Risk Ratio (95% CI)a Heterogeneity (I 2) Age Adults (18-64) Youth (0-17) 82 0.”
BackgroundSerodiagnostics for Severe Acute Respiratory Syndrome–Related Coronavirus 2: A Narrative Review
Cheng, M. P., Yansouni, C. P., Basta, N. E., Desjardins, M., Kanjilal, S., Paquette, K., Caya, C., Semret, M., Quach, C., Libman, M., et al. (2020) · Annals of Internal Medicine · doi:10.7326/m20-2854 · Cited by 135
Self-citationBayesian Analysis of Tests with Unknown Specificity and Sensitivity
(2020) · doi:10.1111/rssc.12435 · Cited by 129
Intrafamilial Exposure to SARS-CoV-2 Induces Cellular Immune Response without SeroconversionPreprint
Gallais, F., Velay, A., Wendling, M.-J., et al. (2020) · medRxiv · doi:10.1101/2020.06.21.20132449 · Cited by 111 · cited 1×
“Firstly, some asymptomatic individuals may not seroconvert, some individuals may have been tested prior to seroconversion, and others may have antibodies that have waned by the time of blood collection, so the data in this study may underestimate the number of SARS-CoV-2 infections [51].”
BackgroundSeroepidemiologic Study Designs for Determining SARS-COV-2 Transmission and Immunity
Clapham, H., Hay, J., Routledge, I., Takahashi, S., Choisy, M., Cummings, D., Grenfell, B., Metcalf, C. J. E., Mina, M., Barraquer, I. R., et al. (2020) · Emerging Infectious Diseases · doi:10.3201/eid2609.201840 · Cited by 94
Early analysis of the Australian COVID-19 epidemic
Price, D. J., Shearer, F. M., Meehan, M. T., McBryde, E., Moss, R., Golding, N., Conway, E. J., Dawson, P., Cromer, D., Wood, J., et al. (2020) · eLife · doi:10.7554/elife.58785 · Cited by 87
Patel, E. U., Bloch, E. M., Grabowski, M. K., Goel, R., Lokhandwala, P. M., Brunker, P. A. R., White, J. L., Shaz, B. H., Ness, P. M., & Tobian, A. A. R. (2019) · Transfusion · doi:10.1111/trf.15415 · Cited by 67
Comparison of donor and general population demographics over time: a BEST Collaborative group study
Goldman, M., Steele, W. R., Angelantonio, E. D., van den Hurk, K., Vassallo, R. R., Germain, M., O’Brien, S. F., & Biomedical Excellence for Safer Transfusion Collaborative (BEST) Investigators (2017) · Transfusion · doi:10.1111/trf.14307 · Cited by 49
Lessons from a rapid systematic review of early SARS-CoV-2 serosurveys
Bobrovitz, N., Arora, R. K., Yan, T., Rahim, H., Duarte, N., Boucher, E., Van Wyk, J., & Evans, T. G. (2020) · medRxiv · doi:10.1101/2020.05.10.20097451 · Cited by 49 · cited 2×
“Given that many serosurveys are not reported in these databases [8] we used four additional search approaches to identify serosurveys reported in the grey literature.”
BackgroundMethodSelf-citationSARS-CoV-2 Seroprevalence Survey Estimates Are Affected by Anti-Nucleocapsid Antibody Decline
Bolotin, S., Tran, V., Osman, S., Brown, K. A., Buchan, S. A., Joh, E., Deeks, S. L., & Allen, V. G. (2021) · The Journal of Infectious Diseases · doi:10.1093/infdis/jiaa796 · Cited by 46
Bayesian analysis of tests with unknown specificity and sensitivityPreprint
Gelman, A., & Carpenter, B. (2020) · medRxiv · doi:10.1101/2020.05.22.20108944 · Cited by 43
The 40 health systems, COVID-19 (40HS, C-19) study
Braithwaite, J., Tran, Y., Ellis, L. A., & Westbrook, J. I. (2020) · International Journal for Quality in Health Care · doi:10.1093/intqhc/mzaa113 · Cited by 35
Byambasuren, O., Dobler, C. C., Bell, K., et al. (2020) · medRxiv · doi:10.1101/2020.07.13.20153163 · Cited by 29 · cited 1×
“1, which aligns with other published analysis [50].”
ResultWorld Health Organization Seroepidemiology Technical Working Group (2021) · Influenza and Other Respiratory Viruses · doi:10.1111/irv.12870 · Cited by 20 · cited 1×
“Where this is not feasible, investigators should at least report the test name, manufacturer, and sensitivity and specificity values to improve data comparability [53].”
BackgroundVanella, P., Wiessner, C., Holz, A., Krause, G., Möhl, A., Wiegel, S., Lange, B., & Becher, H. (2020) · medRxiv · doi:10.1101/2020.05.16.20104117 · Cited by 13 · cited 1×
“Table 5: Differences in seroprevalence estimates by demographic characteristics within studies Factor Reference Group Comparison Group Number of Studies Risk Ratio (95% CI)a Heterogeneity (I 2) Age Adults (18-64) Youth (0-17) 82 0.”
BackgroundSARS-CoV-2 seroprevalence survey estimates are affected by anti-nucleocapsid antibody declinePreprint
Bolotin, S., Tran, V., Osman, S., et al. (2020) · medRxiv · doi:10.1101/2020.09.28.20200915 · Cited by 13
Vanella, P., Wiessner, C., Holz, A., Krause, G., Möhl, A., Wiegel, S., Lange, B., & Becher, H. (2020) · Research Square · doi:10.21203/rs.3.rs-38592/v1 · Cited by 8
Research works printed but not linked: 2
- American Society for Microbiology. Supply Shortages Impacting COVID-19 and Non-COVID Testing [Internet]. 2020 [cited 2021 May 15]. Available from: https://asm.org/Articles/2020/September/Clinical-Microbiology-Supply-Shortage-Collecti-1
- Wolters Kluwer. COVID-19 Tools and Resources for Clinicians: Expert Searches [Internet]. 2020. Available from: https://tools.ovid.com/coronavirus/?utm_source=marketo&utm_medium=email&utm_campaign=0-v035&utm_term=all%20ovid&mkt_tok=eyJpIjoiWkRRM01qWXlPRFV5TnpKbCIsInQiOiIydVZWOUYyRFJJYlg1ZUR4T29sY0tCMGpWcHBVbnpTQWpLTGZQb0RjbnlidUQ2U3lVekxCWjNrN0U4SkZLOE9sM0lHTUlmdXEzMXJcL0pWQkhhSzdGYU92cXJ1RXZ4T3BMc2tmT1ZFMmh2Z09cL0d1MEh6RnowK2NJMGRUbEZSdGQ0VmpQUmpybkljWEpPVnFDUTdnZnlRUT09In0%3D
Cited by
Bergeri, I., Whelan, M. G., Ware, H., Subissi, L., Nardone, A., Lewis, H. C., Li, Z., Ma, X., Valenciano, M., Cheng, B., et al. (2022) · PLOS Medicine · doi:10.1371/journal.pmed.1004107 · Cited by 310
“Our results add global representation and principled estimation of changes in seroprevalence over time as compared to previous evidence syntheses [9,11,12].”
BackgroundResultSelf-citationLewis, H., Ware, H., Whelan, M., Subissi, L., Li, Z., Ma, X., Nardone, A., Valenciano, M., Cheng, B., Noel, K., et al. (2022) · doi:10.1101/2022.02.14.22270934 · Cited by 177
Self-citationLewis, H. C., Ware, H., Whelan, M., Subissi, L., Li, Z., Ma, X., Nardone, A., Valenciano, M., Cheng, B., Noel, K., et al. (2022) · BMJ Global Health · doi:10.1136/bmjgh-2022-008793 · Cited by 173
Self-citationCarrat, F., de Lamballerie, X., Rahib, D., Blanché, H., Lapidus, N., Artaud, F., Kab, S., Renuy, A., Szabo de Edelenyi, F., Meyer, L., et al. (2021) · International Journal of Epidemiology · doi:10.1093/ije/dyab110 · Cited by 138
“0001 Skin lesion (second questionnaire) 384 (3) 13 (5) 39 (4) 0.”
Antibody Responses in COVID-19: A Review
Chvatal‐Medina, M., Cortina, Y. A. M., Grajales, P. J. P., Velilla, P. A., & Rugeles, M. T. (2021) · Frontiers in Immunology · doi:10.3389/fimmu.2021.633184 · Cited by 162
Metadata
- Authors
- Bobrovitz, N., Arora, R. K., Cao, C., Boucher, E., Liu, M., Donnici, C., Yanes-Lane, M., Whelan, M., Perlman-Arrow, S., Chen, J., Rahim, H., Ilincic, N., Segal, M., Duarte, N., Van Wyk, J., Yan, T., Atmaja, A., Rocco, S., Joseph, A., Penny, L., Clifton, D. A., Williamson, T., Yansouni, C. P., Evans, T. G., Chevrier, J., Papenburg, J., & Cheng, M. P.
- Affiliations
- University of Calgary (CA)
- University of Oxford (GB)
- McGill University (CA)
- University of Toronto (CA)
- University of Waterloo (CA)
- McGill University Health Centre (CA)
- Corresponding author
- Bobrovitz, Niklas
- ORCID
- Venue
- PLOS ONE
- Publisher
- Public Library of Science (PLoS)
- Published
- 2021-06-23
- Volume
- 16
- Issue
- 6
- Pages
- e0252617
- ISSN
- 1932-6203 (ISSN-L)
- PMC
- PMC8221784
- OpenAlex
- W3173470851
- Cited by
- 246
- References
- 49
- Citations by year
- 2026: 10 · 2025: 13 · 2024: 33 · 2023: 66 · 2022: 81 · 2021: 43
- FWCI
- 6.52
- Type
- journal article
- Language
- en
- Open access
- gold
- doi.org
- Licence
- Locations
- PLoS ONE (publishedVersion, cc-by)
- medRxiv (acceptedVersion, cc-by-nc-nd)
- PubMed Central (publishedVersion, cc-by)
- PubMed (publishedVersion)
- Federal Open Science Repository of Canada / Le Dépôt fédéral de science ouverte du Canada (submittedVersion, cc-by)
- DOAJ (DOAJ: Directory of Open Access Journals) (submittedVersion, cc-by-sa)
- Funders
- Public Health Agency of Canada via the COVID-19 Immunity Task Force
- Topics
- Health Sciences › Medicine › Infectious Diseases › SARS-CoV-2 and COVID-19 Research
- Physical Sciences › Mathematics › Modeling and Simulation › COVID-19 epidemiological studies
- Health Sciences › Medicine › Infectious Diseases › SARS-CoV-2 detection and testing
- Keywords
- SARS-CoV-2, COVID-19 pandemic, seroprevalence, immunoglobulins, seroepidemiology, racial and ethnic disparities, indigenous peoples, long-term care facilities, perinatal infection, cumulative incidence, public health decision-making, infection risk factors, high-risk groups, SARS-CoV-2 variants
- MeSH terms
- COVID-19, COVID-19 Serological Testing, Adolescent, Adult, Aged, Antibodies, Viral, Child, Health Personnel, Humans, Middle Aged, Sensitivity and Specificity, Incidence, Seroepidemiologic Studies, Young Adult
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.